| 摘要 |
A pharmaceutically acceptable composition and method for solid tumor therapy in a patient in need of such therapy. The composition contains, as the only active agents, the combination of (a) an inhibitor of c-Fos, and (b) an inhibitor of Dusp-1, and optionally (c) an inhibitor of a tyrosine kinase. The composition is administered to the patient in a dosing regimen for a period sufficient to provide therapy for solid tumors. |
